{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-127609","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.286975+00:00","generated_at":"2026-05-15T08:40:47.839991+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vor Biopharma raises $75M via private placement with TCGX for telitacicept development","bullets":["Gross proceeds of $75M from sale of 5.34M shares at $14.05/share to TCGX affiliates.","Closing expected March 30, 2026; no placement agent used.","Proceeds to advance Phase 3 trials for myasthenia gravis and primary Sjögren's disease.","TCGX managing partner expresses confidence in telitacicept's differentiated profile.","Registration rights agreement to file resale registration statement within 30 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-127609","json":"https://secwatch.observer/filing/0001193125-26-127609.json","markdown":"https://secwatch.observer/filing/0001193125-26-127609.md","text":"https://secwatch.observer/filing/0001193125-26-127609.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526127609/0001193125-26-127609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526127609/vor-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:40:47.839991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f348145cc08219d32bd39b496d01eecd2b469a32","claim":"Vor Biopharma Inc. issued 5,338,078 shares of common stock to TCGX for $14.05 per share.","evidence_excerpt":"entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526127609/0001193125-26-127609-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"5,338,078 shares"},{"label":"Purchaser","value":"TCGX"},{"label":"Consideration","value":"$14.05 per share"}],"fact_type":"equity_issuance"},{"claim_id":"5860762d014c3fe3668435c08e0811baff231345","claim":"Vor Biopharma Inc. entered into Securities Purchase Agreement with entities affiliated with TCGX valued at approximately $75.0 million (effective 2026-03-26).","evidence_excerpt":"On March 26, 2026, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with TCGX (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares (the “Shares”) of the Company’s common stock, at a price per Share of $14.05, for gross proceeds of approximately $75.0 million (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526127609/0001193125-26-127609-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"entities affiliated with TCGX"},{"label":"Value","value":"approximately $75.0 million"},{"label":"Effective","value":"2026-03-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}